Search clinical trials for: Toripalimab Nedaplatin Albumin Paclitaxel

Total 1152 results

Guangzhou Institute of Respiratory Disease
Jiangsu HengRui Medicine Co., Ltd.; BGI-Shenzhen

Completed

Efficacy of Neoadjuvant PD-1 Blockade Plus Chemotherapy for Esophageal Squamous Cell Carcinoma

Esophageal Squamous Cell Carcinoma | Immunotherapy

China
Chinese PLA General Hospital

Unknown

Nab-paclitaxel Plus S-1 in Patients With Advanced Pancreatic Cancer (NAPSPAC)

Advanced Pancreatic Cancer

China
Henan Cancer Hospital

Recruiting

Camrelizumab Combined With Albumin-bound Paclitaxel and S-1 in the Treatment of Advanced Gastric Cancer

Advanced Gastric Adenocarcinoma

China
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University

Recruiting

Tirelizumab in Combination With Carboplatin and Albumin-binding Paclitaxel for Neoadjuvant Therapy in HNSCC (HNC-SYSU-001)

Head and Neck Squamous Cell Carcinoma | Oral Cancer

China
Jiangsu Cancer Institute & Hospital

Completed

Chemoradiation Plus Weekly c225 Against Locoregionally Advanced Nasopharyngeal Carcinoma (NPC)

Nasopharyngeal Carcinoma

China
Jinling Hospital, China
Jiangsu Hengrui Pharmaceutical Co., Ltd.

Recruiting

Adbelizumab Combined With Chemotherapy for Neoadjuvant Therapy in Resectable Pancreatic Cancer

Pancreatic Cancer | Neoadjuvant Therapy

China
Sorrento Therapeutics, Inc.

Completed

Bioequivalence Study of IG-001 Versus Nab-paclitaxel in Metastatic or Locally Recurrent Breast Cancer (TRIBECA)

Metastatic Breast Cancer | Locally Recurrent Breast Cancer

United States, Georgia, Moldova, Republic of, Romania, Serbia, Singapore, Ukraine
Sun Yat-sen University

Recruiting

Induction Immuno-chemotherapy and Concurrent Chemoradiotherapy With or Without Apatinib in Unresectable, Locally Advanced Esophageal Squamous Cell Carcinoma

Efficacy | Toxicity | Esophageal Squamous Cell Carcinoma

China
Shanghai Jiao Tong University School of Medicine

Recruiting

Neoadjuvant Anti-PD-1 and TP Versus TPF on Pathological Response in OSCC

Chemotherapy | Oral Squamous Cell Carcinoma | Anti-PD-1 | Neoadjvant Therapy

China
Nanfang Hospital of Southern Medical University
Jiangsu Hengrui Pharmaceutical Co., Ltd.

Recruiting

Adjuvant Chemotherapy Combined With Camrelizumab for ⅡA -ⅢA NSCLC Patients (PANORAMA)

Chemotherapy | Immunotherapy

China
Sun Yat-sen University

Active, not recruiting

Study of Anti-PD-1 Combined With Albumin-Bound Paclitaxel in Patients With Recurrent Cervical Cancer

Recurrent Cervical Cancer

China
Sichuan Cancer Hospital and Research Institute
First Affiliated Hospital Xi'an Jiaotong University; General Hospital of Ningxia... and other collaborators

Unknown

Sintilimab Injection Combined With Concurrent CCRT in Locally Advanced Esophageal Squamous Cell Carcinoma

Locally Advanced Esophageal Squamous Cell Carcinoma

China
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University

Recruiting

4 Courses vs 2 Courses of Pembrolizumab Combined With Carboplatin and Albumin-binding Paclitaxel of Neoadjuvant Therapy in HNSCC (HNC-SYSU-002)

Oral Cancer | HNSCC | PD-1

China
University of Washington
National Cancer Institute (NCI)

Completed

Sargramostim and Paclitaxel Albumin-Stabilized Nanoparticle Formulation in Treating Patients With Advanced Ovarian Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer That Did Not Respond to Previous Chemotherapy

Fallopian Tube Cancer | Peritoneal Cavity Cancer | Ovarian Clear Cell Cystadenocarcinoma | Ovarian Endometrioid Adenocarcinoma | Ovarian Serous Cystadenocarcinoma | Stage IV Ovarian Epithelial Cancer | Brenner Tumor | Recurrent Ovarian Epithelial Cancer | Stage III Ovarian Epithelial Cancer | Ovarian Mucinous... and other conditions

United States
Fifth Affiliated Hospital, Sun Yat-Sen University
Dongguan People's Hospital

Recruiting

The Efficacy and Safety of Neoadjuvant Low-dose Radiotherapy Combined With Chemoimmunotherapy in Locally Advanced HNSCC

Head and Neck Squamous Cell Carcinoma | Neoadjuvant Treatment

China
Vanderbilt-Ingram Cancer Center
National Cancer Institute (NCI)

Terminated

Ph I/II Nab-Paclitaxel & Carboplatin w/Concurrent Radiation Therapy for Unresectable Stg III NSCLC

Lung Cancer

United States
Celgene

Completed

Albumin-bound Paclitaxel (ABI-007) for Patients With Advanced Non-Small Cell Lung Cancer

Non-Small Cell Lung Carcinoma

United States, Canada
Tang-Du Hospital

Recruiting

Zimberelimab Combined With Albumin-bound Paclitaxel and Cisplatin in Neoadjuvant Treatment of LACC

Locally Advanced Cervical Cancer

China
NSABP Foundation Inc
Celgene Corporation

Completed

Therapy With Abraxane and 5-Fluorouracil, Epirubicin, Cyclophosphamide (FEC) for Patients With Breast Cancer

Breast Neoplasms

United States
M.D. Anderson Cancer Center
National Cancer Institute (NCI)

Completed

Pembrolizumab and Paricalcitol With or Without Chemotherapy in Patients With Pancreatic Cancer That Can Be Removed by Surgery

Resectable Pancreatic Carcinoma | Stage I Pancreatic Cancer AJCC v6 and v7 | Stage IA Pancreatic Cancer AJCC v6 and v7 | Stage IB Pancreatic Cancer AJCC v6 and v7 | Stage II Pancreatic Cancer AJCC v6 and v7 | Stage IIA Pancreatic Cancer AJCC v6 and v7 | Stage IIB Pancreatic Cancer AJCC v6 and v7

United States
Beijing Chest Hospital, Capital Medical University

Not yet recruiting

Adebrelimab Plus Chemo and Recaticimab Perioperative Treatment for Resectable NSCLC

Non Small Cell Lung Cancer

China
Fudan University

Unknown

Albumin-bound Paclitaxel Combination With Capecitabine Versus Capecitabine Monotherapy in Paclitaxel/Docetaxel-resistant Advanced Breast Cancer

Breast Cancer

China
University of Michigan Rogel Cancer Center
Celgene Corporation

Terminated

Trial of Combination ABI-007, Carboplatin, and Gemcitabine for First Line Treatment of Advanced Urothelial Cancer

Bladder Cancer | Urothelial Cancer

United States
Liaoning Tumor Hospital & Institute

Not yet recruiting

Adebrelimab Plus Chemotherapy as Neoadjuvant Therapy in Resectable NSCLC Harboring Driver Gene Mutations

Non Small Cell Lung Cancer
Jiuda Zhao

Recruiting

Efficacy and Safety of Sintilimab and Apatinib Combined Chemotherapy in Breast Cancer

Breast Cancer

China
Zhejiang Cancer Hospital
CSPC Ouyi Pharmaceutical Co., Ltd.

Recruiting

Nab-paclitaxel Combined With S-1 as Adjuvant Chemotherapy for Stage Ⅲ Gastric Cancer

Stomach Cancer

China
Guo Xufeng

Recruiting

Perioperative Tislelizumab Plus Chemotherapy for Resectable Thoracic Oesophageal Squamous Cell Carcinoma

Esophageal Squamous Cell Carcinoma | Adjuvant Therapy | Neoadjuvant Chemoimmunotherapy

China
University of Miami

Completed

Abraxane Therapy in Patients With Pancreatic Cancer Who Failed First-Line Gemcitabine Therapy

Pancreatic Cancer

United States, Singapore
Henan Cancer Hospital

Unknown

Apatinib With Albumin-bound Paclitaxel in Patients With Platinum-resistant Recurrent Ovarian Cancer

Ovarian Cancer
Gynecologic Oncology Group
National Cancer Institute (NCI)

Completed

Paclitaxel Albumin-Stabilized Nanoparticle Formulation in Treating Patients With Recurrent or Persistent Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer

Recurrent Ovarian Carcinoma | Fallopian Tube Carcinoma | Primary Peritoneal Carcinoma

United States
Fudan University

Completed

Abraxane in Patients With Visceral Metastases Dominant Metastatic Breast Cancer

Metastatic Breast Cancer

China
Kaiser Permanente
Celgene Corporation

Completed

Phase II Trial of Abraxane in Front Line Therapy of Hormone Refractory Metastatic Prostate Cancer

Prostate Cancer

United States
Southeastern Gynecologic Oncology
Celgene Corporation

Completed

Abraxane Plus Carboplatin for Recurrent Platinum-Sensitive Ovarian Cancer

Ovarian Cancer | Fallopian Tube Cancer | Primary Peritoneal Cancer

United States
Huazhong University of Science and Technology
Chongqing University Cancer Hospital; Peking University People's Hospital; Qilu... and other collaborators

Recruiting

Pd-1 Antibody Combined Neoadjuvant Chemotherapy for Locally Advanced Cervical Cancer

Cervical Cancer | Uterine Cervical Cancer | Uterine Cervical Neoplasm

China
First Affiliated Hospital Xi'an Jiaotong University

Not yet recruiting

Advanced or Metastatic Cholangiocarcinoma

Cholangiocarcinoma
Alliance for Clinical Trials in Oncology
National Cancer Institute (NCI)

Completed

Carboplatin and ABI-007 in Treating Patients With Stage IV Melanoma That Cannot Be Removed By Surgery

Melanoma (Skin)

United States
Xuefei.Wang

Not yet recruiting

HIPEC-AS in Patients With Peritoneal Metastasis of the Stomach or Esophagogastric Junction

Stomach Neoplasms | Peritoneal Metastases
Fudan University

Active, not recruiting

A Phase II Study to Explore the Safety, Tolerability, and Preliminary Antitumor Activity of Sitravatinib Plus Tislelizumab or Combination With Nab-paclitaxel in Patients With Locally Recurrent or Metastatic Triple Negative Breast Cancer (TNBC) (SPARK)

Metastatic Breast Cancer

China
University of California, San Francisco
National Cancer Institute (NCI)

Completed

Lapatinib and Paclitaxel in Treating Patients With Advanced Solid Tumors

Breast Cancer | Gastric Cancer | Esophageal Cancer | Ovarian Cancer | Lung Cancer | Prostate Cancer | Brain and Central Nervous System Tumors | Bladder Cancer | Extragonadal Germ Cell Tumor

United States
Gruppo Oncologico Italiano di Ricerca Clinica
Istituto Toscano Tumori; Temas srl; Clirest s.r.l.; Mipharm S.p.A.

Unknown

Study of Nab-paclitaxel in Sensitive and Refractory Relapsed SCLC (Nabster)

Small Cell Lung Cancer

Italy
Celgene Corporation

Completed

Study of ABI-007 and Taxol in Patients With Metastatic Breast Cancer

Breast Neoplasms | Metastases, Neoplasm

United States
Sun Yat-sen University

Completed

Liposomal Paclitaxel Combined Nedaplatin in Treatment of Advanced or Recurrent Esophageal Carcinoma

Esophageal Carcinoma

China
Fujian Medical University Union Hospital

Not yet recruiting

Immunotherapy Plus Chemotherapy vs. Chemoradiotherapy for Thoracic Squamous Esophageal Carcinoma

Chemotherapy | Radiation Therapy

China
Fondazione IRCCS Istituto Nazionale dei Tumori,...

Completed

Pembrolizumab and Nab Paclitaxel in Patients With Metastatic Urothelial Carcinoma

Metastatic Urothelial Carcinoma

Italy
Memorial Sloan Kettering Cancer Center
Celgene Corporation; National Comprehensive Cancer Network

Completed

Weekly Nanoparticle Albumin-Bound Paclitaxel (Abraxane) + Weekly Cetuximab + Radiation Therapy (IMRT, Intensity-Modulated Radiation Therapy) in Patients With Stage III-IVB Head and Neck Squamous Cell Carcinoma (HNSCC)

HEAD & NECK Cancer

United States
West China Hospital

Recruiting

Single-arm, Multi-center Clinical Study of Pyrotinib Maleate Tablets Combined With Albumin-bound Paclitaxel and Trastuzumab in Neoadjuvant Treatment of Her2-positive Early or Locally Advanced Breast Cancer

Breast Cancer

China
Medstar Health Research Institute

Withdrawn

Capecitabine and Paclitaxel (Albumin-Stabilized Nanoparticle Formulation) in Treating Women Undergoing Surgery for Stage II or Stage III Breast Cancer

Breast Cancer

United States
Shanghai Pulmonary Hospital, Shanghai, China

Not yet recruiting

Adjuvant Toripalimab Plus Chemotherapy for EGFR/ALK Mutation Negative Stage II-IIIB(N2) NSCLC (LungMate-008)

Non Small Cell Lung Cancer
Washington University School of Medicine
Celgene

Completed

Induction Chemotherapy With ACF Followed by Chemoradiation Therapy for Adv. Head & Neck Cancer

Head and Neck Neoplasms

United States
CTI BioPharma

Terminated

A Survival Study for Women With Advanced Lung Cancer Who Have Not Previously Received Chemotherapy. (PIONEER)

NSCLC

United States, Canada, Bulgaria, Romania, Russian Federation, Ukraine, Mexico, Argentina, Hungary, Poland, United Kingdom

Search clinical trials for: Toripalimab Nedaplatin Albumin Paclitaxel

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Thailand

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations